progress
system
sclerosi
ssc
autoimmun
diseas
promin
vascular
damag
multiorgan
fibrosi
sever
autoantibodi
present
sera
patient
ssc
includ
antiendotheli
cell
antifibroblast
antibodi
may
directli
contribut
diseas
pathogenesi
identif
pathogenet
relev
autoantigen
major
goal
autoimmun
disord
ssc
previous
identifi
tetraspanin
transmembran
superfamili
member
peptid
epitop
cgvlgvgiwlaa
key
autoantigen
target
igg
autoantibodi
ssc
tetraspanin
belong
transmembran
superfamili
form
complex
integrin
highli
express
endotheli
cell
fibroblast
seem
role
cell
mobil
adhes
peptid
share
high
degre
homolog
cytomegaloviru
hcmv
deriv
protein
differ
infecti
agent
believ
play
role
immunopathogenesi
ssc
provid
direct
evid
molecular
mimicri
mechan
antibodi
hcmvderiv
protein
link
endotheli
cell
damag
fibrosi
patient
ssc
inde
affinitypurifi
igg
antibodi
deriv
ssc
patient
sera
recogn
wholecel
lysat
induc
apoptosi
endotheli
cell
upon
engag
complex
antibodi
also
abl
caus
fibroblast
activ
prolifer
induc
modul
gene
involv
cell
apoptosi
activ
therefor
propos
hcmv
link
pathogenesi
ssc
particular
subset
antihcmv
antibodi
specif
interact
normal
express
cell
surfac
receptor
share
similar
viral
protein
base
previou
find
aim
firstli
evalu
frequenc
antibodi
patient
ssc
secondli
obtain
fulli
human
mab
abl
block
signal
transduct
follow
recent
describ
method
deriv
antigenspecif
mab
patient
memori
b
cell
describ
gener
function
inact
mab
propos
possibl
biolog
therapi
ssc
total
patient
affect
ssc
enrol
studi
patient
ssc
diffus
cutan
scleroderma
dssc
antibodi
topoisomeras
patient
ssc
limit
cutan
scleroderma
lssc
antibodi
kinetochor
centromer
patient
antinuclear
antibodi
posit
fulfil
american
colleg
rheumatolog
criteria
ssc
moreov
igg
antibodi
hcmv
indic
previou
contact
viru
characterist
patient
summar
tabl
control
sera
obtain
patient
rheumatoid
arthriti
patient
system
lupu
erythematosu
diagnos
follow
american
colleg
rheumatolog
criteria
patient
undifferenti
connect
tissu
diseas
normal
age
sexmatch
individu
two
three
patient
cm
ml
use
gener
mab
affect
diffus
cutan
form
diseas
posit
one
ml
recent
onset
diseas
month
one
patient
pd
suffer
limit
cutan
form
diseas
anticentromer
posit
also
patient
recent
onset
diseas
month
recent
contact
varicella
viru
studi
approv
local
ethic
committe
written
inform
consent
obtain
patient
control
human
endotheli
cell
human
dermal
fibroblast
well
growth
media
purchas
promocel
bioscienc
aliv
heidelberg
germani
endotheli
cell
use
passag
dermal
fibroblast
passag
antibodi
direct
epitop
obtain
pool
igg
ig
deriv
patient
ssc
affin
chromatographi
use
column
flow
column
use
prepar
ig
deplet
antibodi
subset
sequenti
absorpt
column
antibodi
activ
could
detect
antibodi
prepar
elisa
peptideco
plate
human
mab
affin
purifi
use
protein
column
standard
techniqu
amount
purifi
antibodi
quantifi
use
elisa
assay
employ
standard
curv
human
igg
moreov
prepar
also
check
silver
stain
pbmc
cell
isol
ssc
patient
ficollhypaqu
densiti
gradient
centrifug
igg
memori
b
cell
purifi
combin
magnet
fluoresc
cell
sort
briefli
b
cell
isol
bead
miltenyi
biotec
accord
manufactur
instruct
follow
stain
lineag
beckman
coulter
surfac
igd
becton
dickinson
franklin
lake
nj
usa
igm
iga
jackson
immunoresearch
west
grove
pa
usa
igm
iga
igd
b
cell
sort
facsaria
becton
dickinson
sort
b
cell
cultur
cell
per
well
presenc
ebv
cpg
tib
molbiol
genova
itali
irradi
mononuclear
cell
immort
posit
bcell
cultur
clone
one
cell
per
well
presenc
cpg
irradi
mononuclear
cell
peptid
cgvlgvgiwlaa
irrelev
control
peptid
vtlpkdsdvelp
manual
synthes
use
standard
method
solidphas
peptid
synthesi
follow
strategi
minor
modif
synthes
compound
purifi
reversephas
highperform
chromatographi
molecular
weight
final
confirm
electrospray
mass
spectrometri
direct
competit
elisa
method
antibodi
bind
synthet
peptid
describ
synthet
peptid
use
concentr
pb
coat
polystyren
plate
nunc
roskild
denmark
bound
antibodi
detect
alkalin
phosphataseconjug
antiserum
human
igg
sigma
competit
assay
amount
antibodi
gave
maximum
bind
antigen
solid
phase
preincub
differ
amount
competitor
buffer
transfer
antigenco
plate
assay
continu
direct
bind
assay
elisa
assay
detect
serum
antibodi
direct
peptid
serum
sampl
dilut
normal
age
sexmatch
subject
use
control
group
absorb
valu
higher
mean
sd
serum
dilut
control
group
consid
posit
elisa
topoisomeras
centromer
perform
use
commerci
avail
kit
delta
biomed
rome
itali
elisa
recal
antigen
use
commerci
avail
viral
extract
virion
ruschlikon
switzerland
extract
use
concentr
pb
coat
polystyren
plate
nunc
assay
carri
describ
detect
antiplateletderiv
growth
factor
receptoralpha
pdgfra
antibodi
plate
coat
human
pdgfra
millipor
billerica
usa
overnight
block
perform
block
buffer
tween
bsa
sera
dilut
block
buffer
incub
h
room
temperatur
remaind
assay
carri
describ
polyclon
antibodi
gener
new
zealand
white
rabbit
use
standard
techniqu
immun
use
peptid
correspond
aminoacid
residu
cgvlgvgiwlaa
coupl
keyhol
limpet
haemocyanin
antisera
test
elisa
peptideco
plate
antipeptid
fraction
purifi
affin
chromatographi
peptidesepharos
column
fac
analysi
cell
incub
specif
control
antibodi
min
ice
control
antibodi
either
human
polyclon
igg
prepar
human
monoclon
antitetanu
toxoid
igg
antibodi
use
antibodi
bind
reveal
antihuman
igg
antibodi
jackson
immunoresearch
sampl
run
facscan
flow
cytomet
becton
dickinson
endotheli
cell
dermal
fibroblast
lyse
cold
lysi
buffer
mm
tri
ph
sodium
chlorid
mm
magnesium
chlorid
lysat
immunoprecipit
rabbit
antibodi
crosslink
sepharos
elut
protein
resolv
transfer
nitrocellulos
membran
amersham
bioscienc
piscataway
nj
usa
blot
incub
either
rabbit
antibodi
human
antibodi
renaiss
chemiluminesc
kit
nen
boston
usa
use
detect
extent
internucleosom
dna
fragment
quantifi
use
commerci
avail
kit
roch
biochem
indianapoli
usa
accord
manufactur
instruct
cell
cell
cultiv
h
microtit
plate
presenc
absenc
apoptot
stimuli
affinitypurifi
polyclon
antibodi
human
mab
control
antibodi
ssc
serum
ng
tumour
necrosi
factor
tnf
alpha
posit
control
avoid
interfer
serum
complement
compon
serum
heat
inactiv
cell
pellet
incub
lysi
buffer
principl
test
base
detect
mono
oligonucleosom
cytoplasm
fraction
cell
lysat
use
biotinyl
antibodi
histon
peroxidasecoupl
antibodi
dna
result
express
apoptot
cell
od
valu
obtain
ng
tnfalpha
consid
apoptot
cell
death
inhibit
experi
endotheli
cell
preincub
mab
min
cell
wash
complet
medium
either
purifi
polyclon
peptid
antibodi
heatinactiv
ssc
patient
serum
per
well
ad
assay
carri
describ
human
mab
direct
tetanu
toxoid
isotyp
mab
use
control
assess
cell
prolifer
fibroblast
cell
per
well
cultur
variou
interv
time
microtit
plate
presenc
absenc
antibodi
cell
viabil
assess
use
commerci
avail
kit
alexi
biochem
san
diego
ca
usa
akt
phosphoryl
assess
use
commerci
avail
kit
race
akt
activ
motif
carlsbad
ca
usa
kit
detect
total
phosphoryl
akt
increas
level
phosphoryl
akt
indic
cell
activ
incub
time
min
comparison
frequenc
igg
peptid
pdgfra
patient
control
perform
use
utest
comparison
preval
igg
b
cell
produc
clone
specif
recal
antigen
three
patient
analys
carri
use
pearson
chisquar
test
peptid
specif
recogn
serum
igg
patient
studi
direct
elisa
absorb
mean
sd
serum
dilut
competit
elisa
reactiv
detect
individu
sera
healthi
age
sexmatch
control
absorb
mean
sd
fig
patient
rheumatoid
arthriti
patient
system
lupu
erythematosu
patient
undifferenti
connect
tissu
diseas
data
shown
seven
patient
without
antibodi
follow
characterist
five
lssc
two
dssc
diseas
durat
year
activ
phase
bleed
data
indic
peptid
sequenc
peptid
contain
epitop
recogn
sera
nearli
patient
ssc
sinc
antipdgfra
autoantibodi
describ
ssc
autoantibodi
shown
agonist
activ
receptor
test
patient
sera
reactiv
pdgfra
elisa
shown
fig
small
percentag
ssc
patient
igg
antibodi
pdgfra
compar
healthi
control
donor
moreov
antipdgfra
antibodi
level
similar
patient
ssc
healthi
control
fig
data
show
antipdgfra
antibodi
typic
associ
ssc
next
purifi
peptid
fraction
pool
ig
obtain
ssc
patient
found
purifi
antibodi
bound
endotheli
cell
fibroblast
fig
moreov
antibodi
abl
induc
endotheli
cell
apoptosi
fibroblast
prolifer
fig
c
known
key
featur
ssc
sinc
akt
regul
cell
surviv
confirm
fibroblast
activ
prolifer
evalu
akt
phosphoryl
fibroblast
incub
antibodi
fig
confirm
effect
observ
confin
purifi
antibodi
fraction
ig
obtain
patient
complet
deplet
antibodi
subset
test
bind
endotheli
cell
fig
fibroblast
fig
bind
endotheli
cell
fibroblast
cell
surfac
dramat
diminish
fraction
reduct
check
whether
ig
function
effect
endotheli
cell
ig
even
concentr
rais
exert
effect
cell
inde
differ
observ
cell
incub
ig
medium
alon
fig
next
investig
reactiv
pdgfra
purifi
fraction
shown
fig
igg
fraction
bind
pdgfra
wherea
slight
bind
receptor
observ
within
igg
fraction
deplet
activ
moreov
fail
detect
pdgfraactiv
mechan
posit
neg
igg
fraction
data
shown
data
indic
induct
endotheli
cell
apoptosi
fibroblast
activ
inde
confin
purifi
antibodi
fraction
ig
direct
antigen
includ
pdgfra
retain
capac
sinc
confirm
integrinsassoci
tetraspanin
key
autoantigen
target
ssc
possibl
therapeut
strategi
gener
mab
abl
bind
molecul
block
signal
transduct
aim
took
advantag
recent
publish
procedur
allow
dissect
memori
bcell
repertoir
isol
higheffici
bcell
clone
produc
antigenspecif
mab
method
success
use
gener
neutral
antibodi
direct
sever
acut
respiratori
syndrom
coronaviru
reason
autoimmun
bcell
respons
direct
pathogenet
relev
autoantigen
epitop
may
compris
heterogen
subset
autoantibodi
differ
function
properti
therefor
aim
isol
human
mab
abl
bind
function
inact
ssc
patient
pool
igg
memori
b
cell
isol
neg
select
fluoresc
cell
sort
three
patient
ssc
igg
b
cell
immort
ebv
low
number
cell
per
well
presenc
agonist
cpg
oligonucleotid
irradi
mononuclear
cell
igg
produc
bcell
cultur
test
abil
bind
either
peptid
elisa
endotheli
cell
fibroblast
fac
analysi
three
antigen
test
tabl
noteworthi
frequenc
clone
produc
igg
antibodi
direct
epitop
much
higher
frequenc
clone
produc
antibodi
direct
scleroderma
autoantigen
patient
cm
moreov
clone
produc
autoantibodi
direct
centromer
detect
two
patient
suggest
frequenc
iggproduc
b
cell
much
higher
frequenc
b
cell
direct
classic
scleroderma
autoantigen
centromer
also
test
clone
reactiv
pdgfra
howev
could
detect
reactiv
within
clone
test
tabl
surprisingli
three
patient
analys
frequenc
iggproduc
bcell
clone
significantli
higher
frequenc
clone
produc
igg
recal
antigen
test
measl
viru
varicella
viru
rotaviru
tabl
b
tabl
patient
pd
high
frequenc
igg
varicella
viru
howev
recent
contact
viru
moment
venopunctur
data
indic
autoreact
b
memori
cell
present
high
frequenc
patient
ssc
mab
bound
peptid
endotheli
cell
fibroblast
test
function
assay
use
approach
among
iggproduc
clone
select
mab
igg
k
bound
effect
endotheli
cell
fibroblast
therefor
nearli
igg
produc
gener
clone
function
activ
figur
show
characterist
mab
bind
endotheli
cell
fibroblast
shown
fac
analysi
panel
ii
recogn
molecul
shown
western
blot
panel
b
iii
induc
endotheli
cell
apoptosi
panel
c
fibroblast
activ
prolifer
panel
e
f
interestingli
endotheli
cell
preincub
mab
undergo
apoptosi
serum
patient
ssc
polyclon
antibodi
direct
purifi
patient
ad
cultur
fig
indic
mab
abl
block
activ
pathogen
serum
autoantibodi
studi
show
molecul
repres
main
autoantigen
target
pathogen
autoantibodi
ssc
inde
serum
igg
antibodi
direct
molecul
present
nearli
patient
ssc
antibodi
abl
induc
vascular
damag
fibroblast
prolifer
two
key
featur
diseas
wherea
antibodi
depriv
anti
activ
pathogenet
relev
sinc
unabl
induc
cell
damag
autoantibodi
specif
pdgfra
detect
serum
patient
ssc
antibodi
display
agonist
activ
demonstr
induct
pdgfr
phosphoryl
cultur
fibroblast
could
detect
antipdgfra
activ
ssc
sera
weak
reactiv
pdgfra
detect
igg
fraction
depriv
activ
importantli
antibodi
popul
fail
activ
pdgfr
result
consist
recent
report
rais
question
regard
exist
andor
signific
agonist
autoantibodi
pdgfr
ssc
b
memori
cell
secret
igg
antibodi
direct
molecul
present
high
frequenc
bcell
repertoir
patient
ssc
shown
lower
number
bcell
clone
produc
igg
recal
antigen
test
measl
viru
varicella
viru
rotaviru
nearli
absenc
clone
produc
antitopoisomeras
anticentromer
antibodi
describ
gener
human
mab
deriv
ssc
patient
specif
bind
molecul
endotheli
cell
fibroblast
antibodi
function
inact
sinc
induc
endotheli
damag
fibroblast
prolifer
indic
autoreact
bcell
repertoir
direct
particular
autoantigen
autoantibodi
differ
function
activ
present
use
biolog
therapi
ssc
disappoint
far
inde
case
treat
antitnfalpha
agent
give
conflict
result
biolog
therapi
specif
design
ssc
mab
direct
transform
growth
factorbeta
profibrot
cytokin
thought
play
pivot
role
pathogenesi
multiorgan
fibrosi
typic
scleroderma
unfortun
therapi
seem
efficaci
treatment
diseas
imatinib
mesyl
small
molecul
inhibitor
exert
select
dual
inhibit
transform
growth
factorbeta
plateletderiv
growth
factor
receptor
pathway
seem
use
treatment
skin
fibrosi
howev
affect
vascular
damag
pivot
featur
diseas
autolog
haematopoiet
stem
cell
transplant
anoth
possibl
therapeut
option
patient
earli
diffus
ssc
aim
achiev
remiss
diseas
prospect
random
trial
progress
evalu
safeti
efficaci
treatment
conclus
data
suggest
select
fulli
human
mab
gener
describ
may
repres
ideal
candid
novel
therapeut
intervent
ssc
sinc
target
molecul
play
fundament
role
pathogenesi
diseas
italian
ministri
scientif
research
technolog
murst
cl
rc
ap
